Marker Therapeutics, Inc.
MRKRNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $3.5M | $6.6M | $3.3M | $3.5M | $1.2M | $466,785 |
| Operating income | −$12.9M | −$11.1M | −$14.6M | −$19.8M | −$39.5M | −$28.9M |
| Net income | −$12.2M | −$10.7M | −$8.2M | −$29.9M | −$41.9M | −$28.7M |
| Total assets | $19.1M | $22.0M | $17.1M | $34.4M | $68.1M | $45.6M |
| Total liabilities | $2.3M | $3.5M | $3.1M | $14.8M | $24.1M | $18.3M |
| Equity | $16.8M | $18.6M | $14.1M | $19.6M | $44.0M | $27.3M |
| EPS (diluted) | $-0.79 | $-1.19 | $-0.94 | $-3.58 | $-5.47 | $-0.61 |
| Shares out. | 10.7M | 8.9M | 8.8M | 83.1M | 50.7M | 46.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −363.5%
- Net margin
- −343.0%
- Return on equity
- −72.4%
- Return on assets
- −63.8%
- Return on capital (ROCE)
- −76.7%
- Liabilities / assets
- 11.9%
- Debt / equity
- 0.14×
- Book value / share
- $1.57
- Revenue growth (YoY)
- −46.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -69.50distress
- Accruals / assets
- −0.8%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2016
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2014
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2014
- NT 10-Qmissed a reporting deadline ↗May 15, 2014
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2014
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2013
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Recruitingreadout ~2028-02-28Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- Phase 1Not Yet Recruitingreadout ~2028-07-16MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
- Phase 1Recruitingreadout ~2029-09Safety of MT-401-OTS in Patients With Relapsed AML or MDS
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- New Enterprise Associates 16, L.P.Activist (13D)Nov 17, 2025
- Alyeska Investment Group, L.P.Passive (13G)Nov 14, 2025
- Wilson John RobertActivist (13D)Aug 20, 2025
- Blue Owl Capital Holdings LpPassive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 244,966 | 3.8 | +62.7% |
| Apr 30, 2026 | 150,562 | 1.9 | -21.0% |
| Apr 15, 2026 | 190,658 | 1.0 | -62.8% |
| Mar 31, 2026 | 512,684 | 4.5 | -14.3% |
| Mar 13, 2026 | 598,274 | 4.7 | -8.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Amended charter or bylaws · Shareholder voteMay 4, 2026
- Results of operationsMar 19, 2026
- Item 5.08Feb 9, 2026
- Results of operationsNov 14, 2025
- Director / officer change · Other material eventNov 5, 2025
- Other material eventOct 6, 2025
- Regulation FD disclosureAug 26, 2025
- Changed auditorAug 12, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QMay 15, 2026
- 8-KFORM 8-KMay 4, 2026
- DEFA14AMar 20, 2026
- ARSMar 20, 2026
- DEF 14AFORM DEF 14AMar 20, 2026
- 8-KFORM 8-KMar 19, 2026
- 10-KMar 18, 2026
- PRE 14AFORM PRE 14AMar 10, 2026
- 8-KFORM 8-KFeb 9, 2026
- 4PRIMARY DOCUMENTNov 19, 2025
- 4PRIMARY DOCUMENTNov 19, 2025
- 4OWNERSHIP DOCUMENTNov 19, 2025
- SCHEDULE 13D/ANov 17, 2025
- SCHEDULE 13G/ANov 14, 2025
- 8-KFORM 8-KNov 14, 2025
Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.